Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06079164 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06079164 · ClinicalTrials.gov record · last posted 2026-08-25

Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma

StatusActive, Not Recruiting
PhasePhase 1
Started2023-11-09
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This study will have two Phases: Phase 1a and Phase 1b. The goal of Phase 1a of this clinical study is to learn more about the safety, tolerability and dosing of study drug KITE-197, in participants with relapsed or refractory large B-cell lymphoma (r/rLBCL). The goal of Phase 1b of this clinical study is learn about the effectiveness of the recommended dose of KITE-197 in participants with r/r LBCL. The primary objectives of this study are: Phase 1a: To evaluate the safety of KITE-197 in participants with r/r LBCL and determine the target dose level for Phase 1b. Phase 1b: To evaluate the efficacy of KITE-197 in participants with r/r LBCL as measured by the complete remission (CR) rate.

Protocol amendment history 3 changes detected by DataLookout

2026-08-26
Enrollment reduced: 39 → 21 participants
2026-08-26
Primary completion pushed: 2026-07 → 2026-11
2026-08-26
Completion pushed: 2026-07 → 2026-11
Trial Details
NCT Number NCT06079164
Lead Sponsor Kite, A Gilead Company
Conditions Relapsed/Refractory Large B-cell Lymphoma
Enrollment 21 participants
Start Date 2023-11-09
Primary Completion 2026-11 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2026-08-25